通过对蛋白酶抑制剂茚地那韦国内外知识产权保护状况的初步分析,以及茚地那韦国际和国内的申请量、申请地区、申请人、保护状况和期限等方面统计,可见国外原研企业对于茚地那韦专利申请已逐年下降,但目前专利仍对该药有一定的保护力度,该药在合成方法、衍生物、新剂型、新用途等方面尚有较大的研发和保护空间,相关医药企业仍可从这些方面对该药进行研究改进或创新。 Through the preliminary analysis of protease inhibitor indinavir domestic and international intellectual property protection situation, as well as indinavir international and domestic applications, the application area, the applicant, the status of protection and the deadline and other aspects of statistics, shows that foreign original research enterprise for Indinavir patent applications have declined year by year, but the current patent still has a certain degree of protection of the drug, the drug in the synthesis methods, derivatives, new dosage forms, new uses and so there is a greater R & D and protection of space, the relevant Pharmaceutical companies can still from these aspects of the drug research to improve or innovation.